Research programme: filariasis therapeutics - Eisai/Liverpool School of Tropical Medicine/University of Liverpool
Latest Information Update: 05 Jul 2016
At a glance
- Originator Eisai Co Ltd; Liverpool School of Tropical Medicine; University of Liverpool
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Filariasis
Most Recent Events
- 24 Jun 2016 Anacor Pharmaceuticals has been acquired by Pfizer
- 20 Mar 2014 Early research in Filariasis in United Kingdom (unspecified route)